Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073896 | 0.91 | POLB (0.59) | POLBNPSR1ALDH1A1MAPTP2RX7 | |
| SCHEMBL14073616 | 0.84 | MAPT (0.58) | POLBALDH1A1MAPTKMT2ATRPV1 | |
| SCHEMBL14073372 | 0.84 | KMT2A (0.54) | POLBALDH1A1MAPTKMT2A | |
| SCHEMBL4576855 | 0.81 | ALDH1A1 (0.62) | POLBALDH1A1MAPTKMT2ATRPV1 | |
| SCHEMBL27652513 | 0.81 | MAPT (0.62) | POLBALDH1A1MAPTKMT2ATRPV1 | |
| SCHEMBL14073095 | 0.79 | MAPT (0.60) | POLBALDH1A1MAPTKMT2ATRPV1 | |
| SCHEMBL14072971 | 0.77 | GAA (0.61) | POLBALDH1A1MAPTP2RX7LMNA | |
| SCHEMBL14073071 | 0.77 | PARP1 (0.50) | POLBALDH1A1MAPTKMT2A | |
| SCHEMBL14073612 | 0.77 | MAPT (0.58) | POLBALDH1A1MAPTKMT2ATRPV1 | |
| SCHEMBL14073510 | 0.76 | MAPT (0.56) | POLBALDH1A1MAPTKMT2ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | POLB 2906/4885NPSR1 1482/4885ALDH1A1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.